Vagus Nerve Stimulation Market 2030: Rising Awareness and Its Effects

Vagus Nerve Stimulation Market Overview

The global vagus nerve stimulation (VNS) market was valued at USD 434.40 million in 2022 and is anticipated to reach USD 970.6 million by 2030, expanding at a compound annual growth rate (CAGR) of 10.61% from 2023 to 2030. Key factors contributing to this growth include an aging population, the launch of technologically advanced devices, growing use of VNS as an adjunct therapy, and rising incidences of chronic conditions such as epilepsy and migraine. Additionally, significant unmet medical needs in these disease areas further drive market expansion.

Other influential growth drivers include the increasing prevalence of neurological and lifestyle-related disorders, external funding for research and development (R&D), and a growing preference for minimally invasive procedures. VNS devices are used primarily in managing chronic illnesses such as epilepsy and depression. These devices function by delivering electrical impulses to the vagus nerve and typically consist of two components: a pacemaker and an electrode.

In epilepsy treatment, where approximately 30% of patients do not respond to conventional medication, VNS provides an alternative solution, with data showing a 50% reduction in seizure frequency. The high efficacy of VNS devices in managing epilepsy and treatment-resistant depression positions them as a valuable therapeutic tool, bolstering market demand over the next six years.

Order a free sample PDF of the Vagus Nerve Stimulation Market Intelligence Study, published by Grand View Research.

Key Market Trends & Insights

• Regional Leadership: In 2022, North America accounted for 59.92% of the global market share due to robust government initiatives and awareness campaigns for epilepsy and depression.
• Product Segment: The implantable VNS device segment held over 59.0% of the revenue share in 2022, driven by rising incidences of depression, epilepsy, and chronic headaches.
• Biomaterials: Devices made with metallic biomaterials led the market with a 49.0% share in 2022, supported by increased R&D efforts. This segment is expected to maintain its dominance through 2030.
• Applications: The epilepsy segment held 58.25% of the market share in 2022 due to growing regulatory approvals and the high global prevalence of the condition.

Market Size & Forecast

• 2022 Market Size: USD 434.40 Million
• 2030 Projected Market Size: USD 970.6 Million
• CAGR (2023–2030): 10.61%
• Top Region (2022): North America
• Fastest Growing Region: Asia Pacific

Key Companies & Competitive Insights

Leading market players are actively engaged in product development, technological innovations, and strategic mergers and acquisitions to enhance market presence. For instance, LivaNova secured CE Mark approval in March 2020 for its VNS Therapy System – Symmetry – aimed at treating difficult-to-manage depression.

Companies are also collaborating with academic and research institutions to broaden the scope of VNS applications through clinical trials. The demonstrated success of VNS in treating epilepsy and treatment-resistant depression (TRD), especially in developed regions, is expected to unlock significant growth opportunities.

Innovative entrants such as electroCore, MicroTransponder, Inc., and Parasym are recognized for delivering competitive, cost-effective, and technologically advanced solutions. For example, in November 2017, electroCore raised over USD 70 million in Series B funding to support the commercialization of its gammaCore product and continued clinical development of non-invasive VNS (nVNS) devices.

Notable Market Players:

• LivaNova LLC (formerly Cyberonics)
• electroCore
• Cerebral Rx
• MicroTransponder, Inc.
• Parasym

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global vagus nerve stimulation market is on a robust growth trajectory, driven by increasing prevalence of neurological disorders, strong clinical efficacy in epilepsy and TRD, and rapid technological innovations. With North America leading in adoption and Asia Pacific emerging as the fastest-growing region, the market presents significant opportunities for both established players and new entrants. Continued R&D investment, regulatory support, and product advancements are expected to further fuel the market through 2030.